Details for Patent: 9,376,680
Which drugs does patent 9,376,680 protect, and when does it expire?
Patent 9,376,680 protects QFITLIA and is included in one NDA.
This patent has sixty-one patent family members in twenty-five countries.
Summary for Patent: 9,376,680
| Title: | Serpinc1 iRNA compositions and methods of use thereof |
| Abstract: | The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia. |
| Inventor(s): | Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin Maier, Klaus Charisse, Satyanarayana KUCHIMANCHI, Kallanthottathil G. Rajeev, Muthiah Manoharan |
| Assignee: | Genzyme Corp |
| Application Number: | US14/806,084 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,376,680
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme Corp | QFITLIA | fitusiran sodium | SOLUTION;SUBCUTANEOUS | 219019-001 | Mar 28, 2025 | RX | Yes | Yes | 9,376,680 | ⤷ Start Trial | Y | Y | ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA A OR B WITH OR WITHOUT FACTOR VIII OR IX INHIBITORS | ⤷ Start Trial | ||
| Genzyme Corp | QFITLIA | fitusiran sodium | SOLUTION;SUBCUTANEOUS | 219019-002 | Mar 28, 2025 | RX | Yes | Yes | 9,376,680 | ⤷ Start Trial | Y | Y | ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA A OR B WITH OR WITHOUT FACTOR VIII OR IX INHIBITORS | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,376,680
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 090869 | ⤷ Start Trial | |||
| Argentina | 127137 | ⤷ Start Trial | |||
| Australia | 2013251494 | ⤷ Start Trial | |||
| Australia | 2018200469 | ⤷ Start Trial | |||
| Australia | 2020202705 | ⤷ Start Trial | |||
| Australia | 2022279381 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
